ArticleJournal of the American Chemical Society2015
A New Strategy for Smoking Cessation: Characterization of a Bacterial Enzyme for the Degradation of Nicotine.
Article in Journal of the American Chemical Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Ancestral evolution of oxidase activity in a class of (S)-nicotine and (S)-6-hydroxynicotine-degrading flavoenzymes.The Journal of biological chemistry · 2025Article
- From micro to macro, nanotechnology demystifies acute pancreatitis: a new generation of treatment options emerges.Journal of nanobiotechnology · 2025Review
- Reduction of nicotine content in tobacco through microbial degradation: research progress and potential applications.Biotechnology for biofuels and bioproducts · 2024Review
- Non-small-molecule therapeutics for drug addiction: From pharmaco-kinetics modulating to synthetic biology.Fundamental research · 2024Review
- Breaking the habit: isolating nicotine-degrading bacteria in undergraduate microbiology teaching labs.Journal of microbiology & biology education · 2024Article
- Rational Design of a Flavoenzyme for Aerobic Nicotine Catabolism.bioRxiv : the preprint server for biology · 2024Article
- Genomic and Metagenomic Insights into the Distribution of Nicotine-degrading Enzymes in Human Microbiota.Current genomics · 2024Article
- Directed evolution unlocks oxygen reactivity for a nicotine-degrading flavoenzyme.Nature chemical biology · 2023Article
- Research Progress of Antioxidant Nanomaterials for Acute Pancreatitis.Molecules (Basel, Switzerland) · 2022Review
- Binding Interface and Electron Transfer Between Nicotine Oxidoreductase and Its Cytochrome c Electron Acceptor.Biochemistry · 2022Article
- A cytochrome c is the natural electron acceptor for nicotine oxidoreductase.Nature chemical biology · 2021Article
- Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models.Neuropharmacology · 2020Review
- Article
- Optimization of a nicotine degrading enzyme for potential use in treatment of nicotine addiction.BMC biotechnology · 2019Article
- An enzymatic approach reverses nicotine dependence, decreases compulsive-like intake, and prevents relapse.Science advances · 2018Article
- The nicotine-degrading enzyme NicA2 reduces nicotine levels in blood, nicotine distribution to brain, and nicotine discrimination and reinforcement in rats.BMC biotechnology · 2018Article
- Crystallography Coupled with Kinetic Analysis Provides Mechanistic Underpinnings of a Nicotine-Degrading Enzyme.Biochemistry · 2018Article
- An enzymatic advance in nicotine cessation therapy.Chemical communications (Cambridge, England) · 2018Article
- A nanoparticle-based nicotine vaccine and the influence of particle size on its immunogenicity and efficacy.Nanomedicine : nanotechnology, biology, and medicine · 2017Article
- Structural Analysis Provides Mechanistic Insight into Nicotine Oxidoreductase from Pseudomonas putida.Biochemistry · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Smoking is the leading cause of preventable diseases; thus, effective smoking cessation aids are crucial for reducing the prevalence of cigarette smoking and smoking-related illnesses. In our current campaign we offer a nicotine-degrading enzyme from Pseudomonas putida, NicA2, a flavin-containing protein. To explore its potential, a kinetic evaluation of the enzyme was conducted, which included determination of K(m), k(cat), buffer/serum half-life, and thermostability. Additionally, the catabolism profile of NicA2 was elucidated to assess the potential toxicity of the nicotine-derived products. In characterizing the enzyme, a favorable biochemical profile of the enzyme was discovered, making NicA2 a prospective therapeutic candidate. This approach provides a new avenue for the field of nicotine addiction therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.